Status:
COMPLETED
Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
Lead Sponsor:
Pfizer
Conditions:
Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
This study will describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia (CML) used in a real world clinical practice setting.
Eligibility Criteria
Inclusion
- Patients with a diagnosis of Ph+ CML aged ≥18 years at bosutinib initiation.
- Patients prescribed bosutinib (irrespective of the phase of their disease) EITHER in normal clinical practice since it received marketing authorisation (27 March 2013) by the EMA OR via the compassionate use programme prior to marketing authorization.
- Where required, evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Exclusion
- Patients prescribed bosutinib as part of an interventional clinical trial programme.
- Patients initiated on bosutinib less than 3 months prior to data collection taking place.
- Patients prescribed bosutinib as exclusively post-allograft therapy.
Key Trial Info
Start Date :
October 8 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 8 2021
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT05363488
Start Date
October 8 2021
End Date
October 8 2021
Last Update
April 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
eatson West of Scotland Cancer Centre
Glasgow, United Kingdom